Status:
COMPLETED
Synergistic Effect of Vitamin E & D in Reducing Risk of Effects Associated With Atypical Anti-psychotics
Lead Sponsor:
Dr Rabia Arshad
Conditions:
Antipsychotics and Neuroleptics Toxicity
Eligibility:
All Genders
20-70 years
Phase:
NA
Brief Summary
Atypical antipsychotic drugs are commonly used to treat psychiatric illnesses but they are significantly associated with side effects including acute dystonia, akathisia, parkinsonism (rigidity and tr...
Detailed Description
Inclusion Criteria: 1\. Patients using antipsychotic medications such as quetiapine, olanzapine, or risperidone 3. Participants who are between the ages of 20 - 70 years 3. Both gender patients male ...
Eligibility Criteria
Inclusion
- Those using antipsychotic medications such as quetiapine, olanzapine, or risperidone.
- Participants who are between the ages of 20 - 70 years are both sex male and female
- participants who are taking a combination of one or two antipsychotics.
- Participants who were under antipsychotic therapy and not diagnosed with type 2 diabetes mellitus.
Exclusion
- Patients at mental hospitals are mostly women who are either pregnant or nursing.
- Patients who were taking anticonvulsants, ketoconazole, or corticosteroids, or who had a history of other mental or neurologic illnesses, as well as those who used phosphor, calcium, vitamin D supplements or teriparatide, were not included in the study.
- Participants were also ruled out if they had preexisting conditions including renal or hepatic failure or a parathyroid disease
- \-
Key Trial Info
Start Date :
January 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 10 2021
Estimated Enrollment :
140 Patients enrolled
Trial Details
Trial ID
NCT06200584
Start Date
January 1 2021
End Date
June 10 2021
Last Update
January 11 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Jinnah Post Graduate Medical Centre
Karachi, Sindh, Pakistan, 75510